• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia.

作者信息

Adrianzen-Herrera Diego, Jordan-Bruno Ximena, Devitt Katherine A, Conant Joanna L, Gardner Juli-Anne

机构信息

Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.

Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT, USA.

出版信息

Leuk Res. 2021 Jan;100:106494. doi: 10.1016/j.leukres.2020.106494. Epub 2020 Dec 15.

DOI:10.1016/j.leukres.2020.106494
PMID:33387682
Abstract
摘要

相似文献

1
Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia.难治性急性髓性白血病患者接受BCL2抑制剂治疗后获得性BCR-ABL1融合和IDH1克隆进化
Leuk Res. 2021 Jan;100:106494. doi: 10.1016/j.leukres.2020.106494. Epub 2020 Dec 15.
2
A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.一种针对急性髓系白血病中突变异柠檬酸脱氢酶的合成致死方法。
Nat Med. 2015 Feb;21(2):113-4. doi: 10.1038/nm.3796.
3
IDH1/2 mutations and BCL-2 dependence: an unexpected Chink in AML's armour.IDH1/2 突变与 BCL-2 依赖性：AML 盔甲上的意外裂痕。
Cancer Cell. 2015 Mar 9;27(3):323-5. doi: 10.1016/j.ccell.2015.02.013.
4
Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine.在一位同时患有 BCR-ABL1 和 CBFB 重排的复发 AML 患者中，采用 Venetoclax 和 5-氮杂胞苷联合治疗后达到不完全血液学恢复的完全缓解持续存在。
Chemotherapy. 2020;65(1-2):51-53. doi: 10.1159/000508658. Epub 2020 Jun 22.
5
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.异柠檬酸脱氢酶1和2突变在急性髓系白血病中诱导对BCL-2的依赖性。
Nat Med. 2015 Feb;21(2):178-84. doi: 10.1038/nm.3788. Epub 2015 Jan 19.
6
Apoptosis targeted therapies in acute myeloid leukemia: an update.急性髓细胞白血病的凋亡靶向治疗：最新进展。
Expert Rev Hematol. 2020 Dec;13(12):1373-1386. doi: 10.1080/17474086.2020.1852923. Epub 2020 Dec 6.
7
[Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].Bcl-2抑制剂维奈克拉联合方案治疗30例IDH1/2突变急性髓系白血病的临床分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):691-694. doi: 10.3760/cma.j.issn.0253-2727.2022.08.014.
8
Emergence of a BCR::ABL1 rearrangement following a uniquely complex clonal evolution pattern in a patient undergoing Fms-like tyrosine kinase 3 inhibitor therapy for acute myeloid leukemia.
Int J Lab Hematol. 2023 Apr;45(2):e24-e27. doi: 10.1111/ijlh.13973. Epub 2022 Sep 30.
9
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.HOX 基因表达可预测急性髓系白血病对 BCL-2 抑制的反应。
Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8.
10
Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.
Leuk Lymphoma. 2018 Dec;59(12):3010-3012. doi: 10.1080/10428194.2018.1459614. Epub 2018 May 11.